What is Zacks Research's Forecast for BHC Q3 Earnings?

Bausch Health Companies Inc. (NYSE:BHC - Free Report) - Zacks Research lifted their Q3 2026 EPS estimates for shares of Bausch Health Companies in a report issued on Tuesday, October 22nd. Zacks Research analyst R. Department now expects that the company will post earnings of $1.30 per share for the quarter, up from their prior estimate of $1.29. The consensus estimate for Bausch Health Companies' current full-year earnings is $3.61 per share. Zacks Research also issued estimates for Bausch Health Companies' FY2026 earnings at $4.95 EPS.

A number of other equities analysts have also recently issued reports on BHC. Raymond James initiated coverage on shares of Bausch Health Companies in a research note on Wednesday, July 10th. They issued a "market perform" rating and a $8.00 price target on the stock. Scotiabank reduced their price target on shares of Bausch Health Companies from $10.00 to $8.50 and set a "sector perform" rating for the company in a research report on Friday, August 2nd. Jefferies Financial Group decreased their price objective on shares of Bausch Health Companies from $13.00 to $9.00 and set a "buy" rating for the company in a report on Wednesday, August 7th. Evercore ISI upgraded Bausch Health Companies to a "hold" rating in a research note on Tuesday, October 15th. Finally, Truist Financial lowered their price target on Bausch Health Companies from $8.00 to $7.00 and set a "hold" rating on the stock in a report on Thursday, July 25th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Bausch Health Companies currently has a consensus rating of "Hold" and an average target price of $7.33.

Bausch Health Companies Price Performance

BHC stock traded down $0.04 on Wednesday, reaching $8.07. 854,184 shares of the company traded hands, compared to its average volume of 2,962,031. The firm has a fifty day simple moving average of $7.12 and a 200-day simple moving average of $7.07. Bausch Health Companies has a one year low of $3.96 and a one year high of $11.46. The company has a market cap of $2.91 billion, a P/E ratio of -6.48 and a beta of 0.77.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its earnings results on Thursday, August 1st. The company reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.89 by $0.09. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 742.06%. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.33 billion. During the same period in the prior year, the firm earned $0.81 EPS.

Institutional Trading of Bausch Health Companies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Hillsdale Investment Management Inc. increased its stake in shares of Bausch Health Companies by 1,050.8% in the 1st quarter. Hillsdale Investment Management Inc. now owns 3,409,383 shares of the company's stock worth $36,135,000 after purchasing an additional 3,113,123 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Bausch Health Companies by 3,080.9% during the 1st quarter. SG Americas Securities LLC now owns 2,200,526 shares of the company's stock valued at $23,348,000 after buying an additional 2,131,347 shares in the last quarter. Mackenzie Financial Corp grew its stake in shares of Bausch Health Companies by 111.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company's stock valued at $16,612,000 after acquiring an additional 1,252,834 shares during the period. Clearline Capital LP purchased a new stake in Bausch Health Companies in the 2nd quarter worth approximately $6,881,000. Finally, Hein Park Capital Management LP raised its stake in Bausch Health Companies by 56.9% during the 1st quarter. Hein Park Capital Management LP now owns 1,653,579 shares of the company's stock worth $17,544,000 after acquiring an additional 600,000 shares during the period. 78.65% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Seana Carson sold 13,370 shares of the company's stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $6.21, for a total transaction of $83,027.70. Following the completion of the sale, the executive vice president now owns 435,198 shares of the company's stock, valued at $2,702,579.58. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.12% of the stock is currently owned by corporate insiders.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.